A Neuro-Metabolic Syndrome that Needs to Be Discovered: A Child with Late Onset Asparagine Synthetase Deficiency

Abstract

Asparagine synthetase (ASNS) deficiency is a rare inborn error of metabolism caused by a defect in ASNS—a gene encoding asparagine synthetase. It has mainly been described as a neurological phenotype manifesting as severe developmental delay, congenital microcephaly, spasticity, and refractory seizures; it is not associated with any specific dysmorphisms. ASNS deficiency leads to the inability to synthesize a nonessential amino acid in the brain, this explains why the symptoms are primarily neurological. The accumulation of aspartate/glutamate causes increased neuronal apoptosis leading to brain atrophy and increased neuronal excitability leading to seizures. Asparagine levels in plasma and cerebrospinal fluid are not reliable biomarkers for this disorder, therefore diagnosis is mainly obtained by molecular genetics. This disorder is associated with a poor prognosis and there is no treatment except supportive therapy. Prenatal diagnosis is possible. We report a case of a later onset form, c.146G > A (p.Arg49Gln) variant in the ASNS gene detected by molecular analysis using next-generation sequencing; the patient's clinical presentation included microcephaly, regression of developmental milestones, epilepsy, and hyperthermia.

Keywords

asparagine synthetase deficiency - microcephaly - epilepsy - developmental delay

Publikationsverlauf

Eingereicht: 30. Juli 2021

Angenommen: 30. September 2021

Artikel online veröffentlicht:
06. Dezember 2021

• References

• 1 Radha Rama Devi A, Naushad SM. Molecular diagnosis of asparagine synthetase (ASNS) deficiency in two Indian families and literature review of 29 ASNS deficient cases. Gene 2019; 704 (02) 97-102
• 2 Richards NGJ, Kilberg MS. Asparagine synthetase chemotherapy. Annu Rev Biochem 2006; 75 (01) 629-654
• 3 Balasubramanian MN, Butterworth EA, Kilberg MS. Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am J Physiol Endocrinol Metab 2013; 304 (08) E789-E799
• 4 Lomelino CL, Andring JT, McKenna R, Kilberg MS. Asparagine synthetase: Function, structure, and role in disease. J Biol Chem 2017; 292 (49) 19952-19958
• 5 Gupta N, Tewari VV, Kumar M. et al. Asparagine synthetase deficiency-report of a novel mutation and review of literature. Metab Brain Dis 2017; 32 (06) 1889-1900
• 6 Alfadhel M, El-hattab AW. Asparagine synthetase deficiency summary genetic counseling suggestive findings. GeneReviews® [Internet] 2020; 1-13
• 7 Sacharow SJ, Dudenhausen EE, Lomelino CL. et al. Characterization of a novel variant in siblings with asparagine synthetase deficiency. Mol Genet Metab 2018; 123 (03) 317-325
• 8 Costa P, Zanus C, Faletra F. et al. Epileptic encephalopathy with microcephaly in a patient with asparagine synthetase deficiency: a video-EEG report. Epileptic Disord 2019; 21 (05) 466-470
• 9 Genton P, Striano P, Minassian BA. The history of progressive myoclonus epilepsies. Epileptic Disord 2016; 18 (S2): 3-10
• 10 Ruzzo EK, Capo-Chichi JM, Ben-Zeev B. et al. Deficiency of asparagine synthetase causes congenital microcephaly and a progressive form of encephalopathy. Neuron 2013; 80 (02) 429-441
• 11 Duran M. Amino acids. In: Blau N, Duran M, Gibson KM. eds. Laboratory Guide to the Methods in Biochemical Genetics. Berlin Heidelberg: Springer-Verlag; 2008: 68